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Abstract
Background: The World Health Organization (WHO) classification system defines recurrent chromosomal
translocations as the sole diagnostic and prognostic criteria for acute leukemia (AL). These fusion transcripts are
pivotal in the pathogenesis of AL. Clinical laboratories universally employ conventional karyotype/FISH to detect
these chromosomal translocations, which is complex, labour intensive and lacks multiplexing capacity. Hence, it is
imperative to explore and evaluate some newer automated, cost-efficient multiplexed technologies to accommodate
the expanding genetic landscape in AL.
Methods: “nCounter® Leukemia fusion gene expression assay” by NanoString was employed to detect various fusion
transcripts in a large set samples (n = 94) utilizing RNA from formalin fixed paraffin embedded (FFPE) diagnostic bone
marrow biopsy specimens. This series included AL patients with various recurrent translocations (n = 49), normal
karyotype (n = 19), or complex karyotype (n = 21), as well as normal bone marrow samples (n = 5). Fusion gene
expression data were compared with results obtained by conventional karyotype and FISH technology to determine
sensitivity/specificity, as well as positive /negative predictive values.
Results: Junction probes for PML/RARA; RUNX1-RUNX1T1; BCR/ABL1 showed 100 % sensitivity/specificity. A high degree
of correlation was noted for MLL/AF4 (85 sensitivity/100 specificity) and TCF3-PBX1 (75 % sensitivity/100 % specificity)
probes. CBFB-MYH11 fusion probes showed moderate sensitivity (57 %) but high specificity (100 %). ETV6/RUNX1
displayed discordance between fusion transcript assay and FISH results as well as rare non-specific binding in AL
samples with normal or complex cytogenetics.
Conclusions: Our study presents preliminary data with high correlation between fusion transcript detection by a
throughput automated multiplexed platform, compared to conventional karyotype/FISH technique for detection of
chromosomal translocations in AL patients. Our preliminary observations, mandates further vast validation studies to
explore automated molecular platforms in diagnostic pathology.
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Background
In acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL), chromosomal abnormalities play a critical
role in pathogenesis and prognosis [1]. Molecular studies of
these genomic anomalies have identified specific genes
implicated in the process of leukemogenesis [2]. Specific re-
current chromosomal translocations and their fusion tran-
scripts define the current WHO classification system for
acute leukemia (AL) [3]. These genetic aberrations in com-
bination with morphology, immunophenotype and clin-
ical features are used to diagnose distinct types of AL
and thereby dictate therapeutic approaches [4]. Clinical la-
boratories, worldwide, utilize standard FISH technology
with or without conventional karyotype to investigate these
chromosomal translocations [5]. Unfortunately, FISH is a
labour intensive and expensive procedure with the limited
potential for “multiplexing”. These limitations impact diag-
nosis and clinical management. In a small number of AL
sub-types, fusion transcripts can be amplified through re-
verse transcription, polymerase chain reaction (RT-PCR)
methodology [6]. However, clinical application of RT-PCR
is narrow due to variation in breakpoints resulting in
several splice regions [7]. Given these limitations and the
expanding new discoveries of additional recurrent chromo-
somal translocations, there is a need to explore newer
automated technologies to “accommodate” new fusion
transcript discoveries and make this significant clinical
diagnostic testing cost-effective and time efficient.
Digital RNA quantification by NanoString Technologies
is an automated, multiplexed platform, which can accur-
ately measure up to 800 specific targets. “Leukemia Fusion
Gene Expression Assay” by NanoString has a unique design
of junction probes, which target the unique sequence
spanning the fusion junction of the two exons. It has
been claimed that a high degree of sensitivity and specifi-
city has been achieved through sequence modification.
However, no clinical validation data are available to deter-
mine the utility of this automated technology in routine
clinical practice. The objective of this study was to evaluate
the potential application and clinical utility of “Leukemia
Fusion Gene Expression Assay” in the diagnostic sub-
classification of acute leukemia patients. To this effect,
we investigated fusion transcripts in a large cohort of
AML and ALL patients utilizing genomic RNA from
diagnostic bone marrow biopsies. We then correlated
these results with data obtained by routine FISH and
conventional karyotype. Our results provide unique
preliminary data comparing a traditional platform with
a novel automated technology, which provides potential
promise for future adoption in the diagnosis and man-
agement of acute leukemia patients.
Methods
University of Calgary ethics committee approved this
study (REB-13-0380-MODI; dated August 21, 2013).
The diagnosis was confirmed according to the WHO
2008 classification [3]. We employed adequate represen-
tation of samples with recurrent chromosomal transloca-
tion (true positive) in AML (n = 23) and ALL (n = 26)
while AML with normal cytogenetics (n = 19), or complex
cytogenetics (n = 21) and normal bone marrow (n = 5)
samples were used as negative controls (true negative).
Karyotype and fluorescence in-situ hybridization
Complete karyotype analysis at diagnosis was performed
on all leukemic patients and followed a standardized la-
boratory protocol. Banded chromosomes (20 metaphases)
were examined for each patient sample utilizing the G-
banding technique. All patients (100 %) with diagnosis of
ALL (n = 26) were subjected to additional FISH studies
utilizing a panel of four probes (TCF3-PBX1; MLL-AF4;
BCR-ABL and ETV6-RUNX1). Among AML patients,
FISH studies were performed only as second tier test,
as required by findings on karyotype analysis (8/23; 35 %).
Dual color dual fusion or dual color break part FISH probes
(Abbott, Markham ON) were employed to confirm translo-
cations as dictated by clinical requirements or the karyo-
gram. The results of these diagnostic tests performed on
aspirate material were retrieved from patient records for
comparison with digital quantification of fusion transcripts
by NanoString technology (see below).
Gene expression analysis
We employed nCounter® Leukemia Fusion Gene Expres-
sion Assay utilizing the NanoString platform (NanoString
Technologies, Seattle, WA) to evaluate the expression of
fusion transcript (Additional file 1: Table S1). RNA was iso-
lated using the High Pure RNA Paraffin Kit (Roche, Basel,
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Switzerland) utilizing duplicate cores (2-mm), harvested off
areas with maximum tumor cell population in the FFPE
tissue block of diagnostic bone marrow specimen. All bone
marrow biopsies were subjected to a standardized, short
term (1 h 45 min) formic acid decalcification protocol. The
RNA concentration was quantified using UV spectroscopy
(Nanodrop Technologies, Wilmington, DE) and integrity
assessed using a Bio-analyzer 2100 and RNA Nano Chip
assay (Agilent Technologies, Wilmington, DE). The neces-
sary probes and reagents were purchased from NanoString,
and the nCounter analysis was performed according to the
manufacturer’s instructions. Probes were hybridized to
800 ng of total RNA for 20 h at 65 °C. Hybridized reactions
were purified using nCounter Prep Station and data collec-
tion was performed on nCounter Digital Analyzer. Raw
counts were normalized using nSolver Analysis Software
v3.0. Background subtraction was performed for each sam-
ple by subtracting the mean of 8 negative controls from all
data points. Raw counts were further normalized to the six
positive controls, included in each CodeSet, and to the two
housekeeping genes TBP and GUSB.
Sensitivity, specificity, positive and negative predictive values
The sensitivity, specificity, positive and negative predict-
ive values were determined for the seven fusion tran-
scripts by comparing signal-to-noise ratio (SNR). The
median binding value in true negative samples was con-
sidered as background or “noise”. Minimum of ten-fold
or more difference between SNR was considered as the
positive result and was used for further calculations.
Statistical analysis
We used nSolver software v3.0 (NanoString Technolo-
gies) for the normalization of raw counts. Heat map and
principle component analyses were performed on
Qlucore Omics Explorer v3.2 (Lund, Sweden). Statistical
analysis was performed using SPSS software v21.0 (IBM,
Armonk, NY). All computed results having two-sided
P value < 0.05 were considered significant.
Results
A total of 94 (63 AML, 26 ALL and five control bone
marrow) samples were analysed. AML patients included
42 men and 21 women (M: F 2:1) with a median age of
63 years (range 5–87 years). Twenty-six ALL patients
comprised of 17 men and 09 women (M: F 1.8:1) with a
median age of 12 years (range 2–63 years) in this cohort.
Table 1 outlines the sensitivity, specificities, and positive
and negative predictive values for each transcript. Figure 1
outlines, principal component analysis (PCA) plot based on
digital quantification of various fusion transcripts and their
correlation with chromosomal/FISH results. In AML cat-
egory, digital quantification for PML/RARA and RUNX1-
RUNX1T1 correlated 100 % with t(15;17) and t(8;21)
respectively; while non-specific positivity was not seen in
any other samples across entire cohort. CBFB-MYH11 fu-
sion probes showed “false positivity” in AML samples with
complex and normal karyotype. In 4/8 (50 %) of AML sam-
ples with inv(16) or t(16;16); false negative reaction was
noted. In ALL group, BCR-ABL1 fusion probes performed
seamlessly with 100 % sensitivity and specificity. TCF3-
PBX1 andMLL-AF4 fusion probes showed 100 % specificity
but sensitivity ranged up to 86 %. Probes for ETV6/RUNX1
fusion transcript performed poorly and showed only 50 %
sensitivity but 98 % specificity.
Discussion
In WHO classification for AL, chromosomal translocations
are central to diagnosis, sub classification and prognosis.
Conventional cytogenetics, followed by FISH in specific
Table 1 Specificity/sensitivity/positive predictive value and negative predictive value for each transcript as detected by digital RNA
quantification
No (n) Result (Pos./ Neg.) Sensitivity (%) Specificity (%) PPVa (%) NPVb (%)
Acute Myeloid Leukemia (AML)
AML1-ETO 8 8/0 100 100 100 100
PML-RARA 8 8/0 100 100 100 100
CBFB-MYH11 7 4/3 57 100 100 97
Acute Lymphoblastic Leukemia (ALL)
TCF3-PBX1 4 3/1 75 100 100 99
MLL-AF4 7 6/1 85 100 100 99
BCR-ABL 7 7/0 100 100 100 100
ETV6-RUNX1 8 1/7 12 92 50 92
AML - Normal Karyotype 19 0/19 N/A 100 N/A 100
AML - Complex Karyotype 21 1/20 N/A 99 N/A 100
Normal Bone Marrow 5 0/5 N/A 100 N/A 100
aPPV positive predictive value; bNPV negative predictive value
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cases, is the gold standard to detect these chromosomal ab-
errations, but poses the challenge regarding subjectivity,
manual labour, cost and turnaround time. There is a need
to explore automated, multiplexed, throughput and cost-
efficient technologies to serve rapidly expanding discoveries
of novel fusion transcripts in haematological malignancies.
A large cohort of AL samples were analysed by multi-
plexed, automated digital quantification in parallel with
conventional karyotype/FISH technology. We observed a
high degree of correlation (>90 % sensitivity and specificity)
for different translocations that are frequent in clinical
practice. The complete correlation was noted for t(8;21)
between conventional karyotype/FISH and digital fusion
RNA quantification results. This high degree of correlation
can be related to the generation of only two fusion tran-
scripts by this translocation [8]. t(8;21) can also involve
several chromosomes, and these variant rearrangements
can be cryptic and easily overlooked by conventional G-
banding technique [9]. However, it was interesting to note
that none of these cryptic fusion transcripts were detected
in a large cohort of AL patients with normal and complex
cytogenetics. Similarly, almost complete correlation was
also noted for t(15;17); t(9;22) and t(4;11) translocations.
Hence, we established the potential for clinical utility of
this automated throughput platform of digital quantifica-
tion as a possible alternate to current and widely used
FISH technique.
Multiplexed molecular techniques present opportun-
ities in procedural efficiencies, but also pose challenges
regarding cross-reactivity and false positivity [10, 11].
Our extensive series of AL sample sets with normal and
complex cytogenetic provided an adequate safety net to
detect any cross-reactivity of fusion probes. We noted
minimal to no false positive reactions in the majority of
fusion probes. These results are encouraging in our
small patient sample; however, a more robust validation
is required using a larger cohort. In AL patients with
t(12;21) (p13;q22), we noted discordance between FISH
results and ETV6-RUNX1 fusion probe. The breakpoints
in t(12;21) (p13;q22) are variable within the several thou-
sand base pairs of ETV6 as well as RUNX1 introns. In
spite of micro-clustering of breakpoints in ETV6 and
RUNX1 introns, it is still difficult to identify or to se-
quence the breakpoints by even streamlined long‐dis-
tance PCR in t(12;21) [12]. Hence, it appears that fusion
transcript ETV6-RUNX1 is beyond the scope of this
assay at this stage. We also noted that inv(16) showed
the most variable pattern and weak correlation with
FISH results. This translocation results in more than ten
differently sized CBFB-MYH11 fusion transcripts, which
may explain variable sensitivity [13]. The probes against
CBFB-MYH11 showed cross-reactivity with few samples
harbouring normal or complex karyotype. Since there is
marked heterogeneity of breakpoints in MYH11 gene, false
negative rates could be high [14]. False positivity in inv 16
cases has also been reported by RT-PCR [15]. These obser-
vations mandate re-designing of some probes for this assay
for enhanced sensitivity.
Conclusion
Our study demonstrates initial evaluation for fusion
transcript detection by a throughput automated multi-
plexed platform for AL patients as an alternate solution
to current complex, manual and labour intensive karyo-
typing /FISH techniques. Our preliminary study requires
validations by future studies to evaluate these emerging
technologies for their potential adoption in clinical labora-
tories. These expression assays offer significant capacity for
expansion to accommodate additional future fusion tran-
scripts discoveries of diagnostic or prognostic value in AL
patients. It also has an immense ability to include gene ex-
pression signature as a diagnostic or prognostic tool for AL
patients.
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Fig. 1 Principal component analysis (PCA) plot of AL samples with
recurrent translocations [except t (12;21)]; showing discrete clustering
of samples as detected by digital quantification of fusion transcripts,
utilizing NanoString technology
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